Catalysts of the Week
Week of March 24–28, 2026
Six catalysts. The full spectrum of biotech volatility in a single week. A +72% monster. A +35% comeback. A clean data win that still crashed -33%. A dilution trap. A regulatory collapse. And an institutional-grade machine quietly executing. Bio-Score flagged every one of them.
KOD
Kodiak Sciences • $1.4B Mkt Cap • Pre-commercial
GLOW2 Phase 3 Topline Results • Zenkuda (tarcocimab) in Diabetic Retinopathy
Tier 1: Phase 3 DataPrimary Endpoint Crushed+72% Intraday52-Week High
What happened: Zenkuda demolished expectations. 62.5% of patients hit a clinically meaningful DRSS improvement vs. 3.3% for sham (p<0.0001). An 85% risk reduction in sight-threatening complications. Zero intraocular inflammation — a best-in-class safety signal. Stock opened +46% pre-market, then continued ripping to +72% intraday, touching $39+ and new 52-week highs. 1-year return: +650%.
~$39+
Intraday High (Mar 26)
Bio-Score called it: Event Tier 100/100, Urgency 100/100, Materiality 75/100. Score of 93 flagged five days before the readout. Stock delivered +72%. This is what magnitude prediction looks like.
SRPT
Sarepta Therapeutics • $2.3B Mkt Cap • Revenue: $2.2B/yr
Phase 1/2 siRNA Data • SRP-1001 (FSHD1) & SRP-1003 (DM1)
+35% in One SessionDose-Dependent DeliveryEarly-Stage DataDown -77% Prior Year
What happened: Sarepta released its first clinical data from two siRNA programs targeting rare neuromuscular diseases with no approved treatments. Both showed dose-dependent muscle delivery, early biomarker activity, and favorable safety. The data is Phase 1/2 — early by any standard — but for a stock that had fallen 77% over the past year and was trading near 52-week lows at $17.61, any credible pipeline signal carries outsized weight. Stock surged +35% to close at $23.77. $801M cash on hand.
Bio-Score read: Lower score at 70 because Phase 1/2 data is a Tier 3 event with less binary impact. But context matters: a beaten-down stock with $801M cash bouncing off extreme lows is a coiled spring. The magnitude of the move (+35%) was driven by the combination of the data and extreme negative sentiment being unwound. Multiple analysts raised price targets the same day.
INSM
Insmed Inc • $30B Mkt Cap • Revenue: $606M/yr
ENCORE Phase 3b Topline Results (March 23) • ARIKAYCE in MAC Lung Disease
Primary Endpoint Met87.8% vs 57% Culture Conversion+9% on ReadoutCEDAR Q2 2026 Next
What happened: ENCORE delivered clean results on March 23: 87.8% culture conversion vs. 57.0% for placebo (p<0.0001) and improved respiratory symptom scores. This fulfills the FDA’s post-marketing requirement, paving the way for a supplemental NDA and potential label expansion from refractory-only to all MAC lung disease patients. The stock moved from $136 to $148+ over the week — a disciplined +9% move befitting a $30B company. Brinsupri continues executing at $1B+ revenue guidance for 2026. CEDAR readout for hidradenitis suppurativa coming Q2.
Bio-Score read: Score of 85. Unlike the micro-caps on this list, INSM is institutional-grade: $30B market cap, proven commercial team, multiple shots on goal. The +9% move is what controlled volatility looks like for a well-capitalized company. Analysts are raising targets — Jefferies projects $6B+ peak sales for Brinsupri alone. CEDAR in Q2 is the next catalyst.
MAZE
Maze Therapeutics • ~$1.5B Mkt Cap • Pre-revenue
HORIZON Phase 2 Topline Data (March 25) • MZE829 in APOL1-Mediated Kidney Disease
Clinically Meaningful Result-33% Intraday Despite Positive DataPriced to PerfectionInsider Sold $736K 5 Days Before
What happened: This is the most important case study of the week for any biotech trader to understand. The data was positive: 35.6% mean proteinuria reduction (above the 30% clinically meaningful threshold), 61.8% in FSGS patients, well-tolerated. Analysts at Mizuho called it “likely approvable and commercial.” The stock surged +22% in pre-market. Then it crashed -33% intraday. Why? Because MAZE was already up 321% over the past year at ~$49 per share. The data was good — but it wasn’t good enough to justify 321% of pre-catalyst optimism. Meanwhile, an insider sold $736K in shares five days before the readout.
Bio-Score read: This is
“Why Positive Catalysts Don’t Always Mean Positive Price Action” at its most extreme. Good data. Positive analyst reaction. Stock already priced to perfection. Insider selling before the readout. The -33% crash didn’t happen because the data was bad — it happened because 321% of upside was already baked in. Bio-Score predicts magnitude, and the magnitude was massive. The direction was determined by what was already priced in.
KPTI
Karyopharm Therapeutics • $122M Mkt Cap • Revenue: $146M/yr
SENTRY Phase 3 Topline Results (March 24) • Selinexor + Ruxolitinib in Myelofibrosis
Spleen Endpoint Met (50% vs 28%)Symptom Endpoint MissedImmediate $40M Raise$64M Cash / Q2 Runway
What happened: SENTRY delivered a split decision. Spleen volume hit: 50% SVR35 vs. 28%. Symptom score missed. OS signal (HR 0.43) is intriguing but unconfirmed. Then the real story: Karyopharm immediately announced a $30M private placement with RA Capital plus $9.6M in ATM sales. With only $64M cash, going-concern language in filings, and runway into Q2 only, this was a predictable dilution event. The stock went from ~$8.70 pre-data to $6.66.
$6.66
Post-Data + Dilution
Bio-Score called it: Maximum score of 100 — powder keg. Always check cash runway before a binary event. $64M cash + going-concern language = the dilution was predictable regardless of the data outcome.
Article 2’s dilution checklist in real time.
AVXL
Anavex Life Sciences • $254M Mkt Cap
EU Marketing Application Withdrawn (March 25) • Blarcamesine for Alzheimer’s
EMA CHMP Negative-35% CrashNew 52-Week Low: $2.61FDA Pathway Still Open
What happened: Anavex withdrew its EU marketing application after the EMA’s CHMP signaled it would not issue a positive opinion. The stock cratered — down 33% at the open, hitting a 52-week low of $2.61 before settling around $2.74. That’s a -35% single-day crash from the prior close of $4.19. The EMA had flagged concerns as early as November 2025 with a negative trend vote, so the writing was on the wall. The FDA pathway remains open — a Type C meeting in January showed engagement — but the EU rejection raises fundamental questions about the clinical data package.
Bio-Score called it: Score of 100 — maximum powder keg. And the stock delivered maximum volatility: -35% in a single session to a new 52-week low. Bio-Score doesn’t predict direction. It predicts magnitude. AVXL is now down 71% over the past year. The FDA pathway is the last catalyst standing.
// The Takeaway
Six catalysts. Every possible outcome. One algorithm.
KOD delivered a +72% monster on clean Phase 3 data. SRPT bounced +35% off 52-week lows on early pipeline validation. INSM executed quietly with a +9% move on ENCORE success. MAZE proved that positive data doesn’t mean positive price when you’re up 321% going in. KPTI showed why cash runway matters more than data. AVXL crashed -35% on a regulatory rejection.
The MAZE case is the one every trader needs to internalize. The data was good. Analysts were positive. The stock still crashed 33%. Because the move happened before the data, not after it. Pre-catalyst positioning is everything — and that’s exactly what Bio-Score is designed to help you see in advance.
Bio-Score flagged all six. The algorithm predicted magnitude. The direction was up to the data, the cash runway, the pre-catalyst run-up, and the market’s expectations going in. That’s the edge.
See next week’s catalysts
before the market moves.
Bio-Score ranks every upcoming catalyst by predicted volatility magnitude. Updated daily.
Open App →